HTRF analysis of soluble huntingtin in PHAROS PBMCs

Neurology

Volumn 81, Issue 13, 2013, Pages 1134-1140

  Lopatin, Miriam Moscovitch ^a   Goodman, Rachel E ^a   Eberly, Shirley ^b   Ritch, James J ^a   Rosas, H Diana ^a   Matson, Samantha ^a   Matson, Wayne ^c   Oakes, David ^b   Young, Anne B ^a   Shoulson, Ira ^d   Hersch, Steven M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; DOUBLE STRANDED DNA; HUNTINGTIN; PROTEIN; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ADULT; ARTICLE; ASSAY; BLOOD SAMPLING; CAG REPEAT; CHILD; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; GENETIC RISK; HOMOGENEOUS TIME RESOLVED FLUORESCENCE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; INFORMED CONSENT; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MUTANT; OBSERVATIONAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE HUNTINGTON AT RISK OBSERVATIONAL STUDY; QUALITY CONTROL; RISK ASSESSMENT; SCHOOL CHILD; BLOOD; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FRONTAL LOBE; GENETICS; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTICENTER STUDY; MUTATION; OBSERVATION; PATHOLOGY; POSTMORTEM CHANGE; RETROSPECTIVE STUDY; TRINUCLEOTIDE REPEAT;

ADULT; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FRONTAL LOBE; HUMANS; HUNTINGTON DISEASE; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; OBSERVATION; POSTMORTEM CHANGES; RETROSPECTIVE STUDIES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84887374417     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a55ede     Document Type: Article

References (33)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Gutekunst CA, Levey AI, Heilman CJ, et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci USA 1995;92:8710-8714.
3. Di Figlia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-1993. (Pubitemid 27449140)
4. Von sattel JP, Keller C, Cortes Ramirez EP. Huntington's disease: neuropathology. Handb Clin Neurol 2011;100:83-100.
5. Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci USA 2002;99:1002-1007. (Pubitemid 34106625)
6. Hughes A, Jones L. Huntingtin localisation studies: A technical review. PLoS Curr 2011;3:RRN1211.
7. Hersch SM, Rosas HD. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 2008;5: 226-236. (Pubitemid 351446208)
8. Hersch SM. Neuropathology and Pathophysiology of Huntington's Disease in Movement Disorders, 3rd ed. New York: McGraw-Hill; 2011:503-518.
9. Hersch SM, Rosas HD. Biomarkers to Enable the Development of Neuroprotective Therapies for Huntington's Disease: Neurology of Huntington's Disease Applications to Drug Discovery. Boca Raton, FL: CRC Press; 2009.
10. Di Figlia M, Sapp E, Chase K, et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995;14:1075-1081.
11. Weiss A, Abramowski D, Bibel M, et al. Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington's disease. Anal Biochem 2009; 395:8-15.
12. Moscovitch-Lopatin M, Weiss A, Rosas HD, et al. Optimization of an HTRF assay for the detection of soluble mutant huntingtin in human buffy coats: A potential biomarker in blood for Huntington disease. PLoS Curr 2010; 2:RRN1205.
13. Weiss AS, Grueninger D, Abramowski FP, et al. Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count. Anal Biochem 2011;410: 304-306.
14. The Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At-Risk Observational Study) cohort enrolled. Arch Neurol 2006;63:991-996.
15. Ko J, Ou S, Patterson PH. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull 2001;56: 319-329. (Pubitemid 33062356)
16. Trottier Y, Devys D, Imbert G, et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 1995;10: 104-110.
17. Mathis G. Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin Chem 1995;41:1391-1397.
18. Biglan KM, Jankovic J, Eberly E, et al; HSG PHAROS Investigators. Longitudinal analysis of intermediate CAGn repeat length expansion in the Prospective Huntington At-Risk Observational Study (PHAROS). Mov Disord 2010;(suppl 2):S270.
19. Quarrell OW, Rigby AS, Barron L, et al. Reduced penetrance alleles for Huntington's disease: A multi-centre direct observational study. J Med Genet 2007;44:e68.
20. Yoon SR, Dubeau L, de Young M, et al. Huntington disease expansion mutations in humans can occur before meiosis is completed. Proc Natl Acad Sci USA 2003;100: 8834-8838. (Pubitemid 36899184)
21. Huntington Study Group PHAROS Investigators. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
22. Penney JB Jr, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692. (Pubitemid 27212666)
23. Langbehn DR, Brinkman RR, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-277. (Pubitemid 38443548)
24. Gallo V, Egger M, McCormack V, et al. Strengthening the Reporting of Observational studies in Epidemiology- Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. Prev Med 2011;53:377-387.
25. Weiss A, Trager U, Wild EJ, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest 2012;122:3731-3736.
26. Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington's disease mutation: The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330:1401-1406.
27. Chopra V, Quinti L, Kim J, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington disease mouse models. Cell Rep 2012;2:1492-1497.
28. Cowin RM, Roscic A, Bui N, et al. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. Behav Brain Res 2012;229: 308-319.
29. Baldo B, Paganetti P, Grueninger S, et al. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington's disease. Chem Biol 2012;19:264-275.
30. Fox JH, Connor T, Stiles M, et al. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J Biol Chem 2010; 286:18320-18330.
31. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006; 66:250-252. (Pubitemid 43970166)
32. Long JD, Matson WR, Juhl AR, et al. 8OHdG as a marker for Huntington disease progression. Neurobiol Dis 2010;46:625-634.
33. Hu Y, Chopra V, Chopra R, et al. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci USA 2011;108:17141-17146.